Elamipretide effects on the skeletal muscle phosphoproteome in aged female mice

Journal Article
GeroScience, vol. 44, iss. 6, pp. 2913-2924, 2022
Matthew D. Campbell, Miguel Martín-Pérez, Jarrett D. Egertson, Matthew J. Gaffrey, Lu Wang, Theo Bammler, Peter S. Rabinovitch, Michael MacCoss, Wei-Jun Qian, Judit Villen, David Marcinek
AbstractThe age-related decline in skeletal muscle mass and function is known as sarcopenia. Sarcopenia progresses based on complex processes involving protein dynamics, cell signaling, oxidative stress, and repair. We have previously found that 8-week treatment with elamipretide improves skeletal muscle function, reverses redox stress, and restores protein S-glutathionylation changes in aged female mice. This study tested whether 8-week treatment with elamipretide also affects global phosphorylation in skeletal muscle consistent with functional improvements and S-glutathionylation. Using female 6–7-month-old mice and 28–29-month-old mice, we found that phosphorylation changes did not relate to S-glutathionylation modifications, but that treatment with elamipretide did partially reverse age-related changes in protein phosphorylation in mouse skeletal muscle.